SCHEMBL1007347

SCHEMBL1007347

c1ccc2cc(CNC3CCNCC3)ccc2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 12/20 0.56
SLC6A2 P23975 11/20 0.56
SLC6A3 Q01959 10/20 0.56
HTR3A P46098 2/20 0.56
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
HTR7 P34969 1/20 0.56
HTR2B P41595 1/20 0.56
HTR4 Q13639 1/20 0.56
KCNH2 Q12809 5/20 0.50
KDM1A O60341 1/20 0.49
MAOA P21397 1/20 0.49
MAOB P27338 1/20 0.49
DRD4 P21917 1/20 0.46
CCR3 P51677 1/20 0.46
GABRA1 P14867 2/20 0.45
GABRG2 P18507 2/20 0.45
GABRB3 P28472 2/20 0.45
GABRB2 P47870 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6186358 0.98 SLC6A4 (0.55) SLC6A4SLC6A2SLC6A3HTR3AHTR2A
SCHEMBL695325 0.89 MEN1 (0.56) DRD4CCR3
Trifluoroacetic Acid SCHEMBL5040989 0.87 DRD4 (0.48) SLC6A4SLC6A2SLC6A3HTR3AHTR2A
Hydrochloric Acid SCHEMBL2807810 0.87 MEN1 (0.59) DRD4CCR3
SCHEMBL31307735 0.87 SLC6A2 (0.56) SLC6A4SLC6A2SLC6A3HTR3AHTR2A
SCHEMBL15760101 0.84 HRH3 (0.59) SLC6A4SLC6A2SLC6A3DRD4CCR3
SCHEMBL3314997 0.81 IKBKB (0.48)
SCHEMBL375103 0.81 DRD4 (0.46) DRD4CCR3
SCHEMBL22092986 0.80 CHKA (0.47) SLC6A4SLC6A2SLC6A3KCNH2
SCHEMBL658055 0.80 GRIN2B (0.62) SLC6A4SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2268631-A1 AMINOPIPERIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2011-01-05 EP disclosed
EP-1078928-B1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2004-05-12 EP disclosed
US-6486171-B2 USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE LES LABORATOIRES SERVIER (FR) 2002-11-26 US disclosed
US-20020161228-A1 Piperidine compounds ADIR ET COMPAGNIE 2002-10-31 US disclosed
US-6399616-B1 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION LES LABORATOIRES SERVIER (FR) 2002-06-04 US disclosed
EP-1078928-A1 Pyridine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2001-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161228-A1 Piperidine compounds OTC, NPPA, AQP4 SLC6A4 1106/4885SLC6A2 1089/4885SLC6A3 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.